immuno-oncology

Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research

Challenges facing Immuno-Oncology industry

Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research

https://pharmaphorum.com/partner-content/immuno-oncology-challenges-include-identifying-patients-before-therapy-limited-responses-and-biomarker-research/

Strategic Competitive Intelligence and the role of the Microbiome in Immuno-Oncology

Immuno-Oncology Conference – London – September

Strategic Competitive Intelligence and the role of the Microbiome in Immuno-Oncology

https://pharmaphorum.com/partner-content/strategic-competitive-intelligence-and-the-role-of-the-microbiome-in-immuno-oncology/

Updates on Keytruda and future potential therapies advancements in Immuno-Oncology

SMi Group reports on preparations for SMi’s inaugural Immuno-Oncology Conference, which is scheduled to take place 26 –

Updates on Keytruda and future potential therapies advancements in Immuno-Oncology

https://pharmaphorum.com/partner-content/updates-on-keytruda-and-future-potential-therapies-advancements-in-immuno-oncology/

BMS strikes back with lung cancer combo success

Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.

BMS strikes back with lung cancer combo success

https://pharmaphorum.com/news/bms-strikes-back-lung-cancer-combo-success/

Merck’s Keytruda fails in gastric cancer trial

Trial missed overall survival endpoint

Merck’s Keytruda fails in gastric cancer trial

https://pharmaphorum.com/news/mercks-keytruda-fails-gastric-cancer-trial/

CAR-T Congress USA | 20 – 22 March 2018 | Boston

Targeting | Commercialization | Scalability

CAR-T Congress USA | 20 – 22 March 2018 | Boston

https://pharmaphorum.com/events/car-t-congress-usa-20-22-march-2018-boston/

Immuno-Oncology 360° Summit

Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all

Immuno-Oncology 360° Summit

https://pharmaphorum.com/events/immuno-oncology-360-summit/

Immunocore hires Lilly’s Hotchkiss as chief commercial officer

UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.

Immunocore hires Lilly’s Hotchkiss as chief commercial officer

https://pharmaphorum.com/news/immunocore-appoints-andrew-hotchkiss-chief-commercial-officer/

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy

BMS and Infinity aim to overcome triple negative breast cancer resistance to IO

https://pharmaphorum.com/news/bms-infinity-aim-overcome-triple-negative-breast-cancer-resistance-io/

1 2 3 4 5

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Search

Advanced Search

Trending

immuno-oncology